John Leonard, Intellia CEO

In­tel­lia plots piv­otal tri­als for lead pro­grams as it lays out key ob­jec­tives

In­tel­lia has some big plans for the next two years, in­clud­ing piv­otal tri­als for its first two in vi­vo CRISPR ther­a­pies.

The Cam­bridge, MA-based genome edit­ing com­pa­ny on Thurs­day dis­closed its game plan for 2023 and 2024, start­ing with INDs for the in­clu­sion of US sites in stud­ies for NT­LA-2001 and NT­LA-2002 in transthyretin (AT­TR) amy­loi­do­sis with car­diomy­opa­thy and hered­i­tary an­gioede­ma (HAE), re­spec­tive­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.